Maximilian Diehn

Maximilian Diehn co-invented CAPP-Seq (Cancer Personalized Profiling by deep Sequencing), a highly sensitive ctDNA detection method that has become a foundational technology for MRD assessment in lung cancer and other solid tumors. His research has demonstrated that ctDNA dynamics during and after radiation therapy predict treatment response and recurrence with high accuracy. He leads clinical studies integrating MRD detection into radiation oncology treatment planning and surveillance protocols.